Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

414
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
414
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

310
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
310
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

270
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
270
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

786
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
786
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

273
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
273
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

1.5K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond the Trials: Real-World Insights into Tezepelumab Efficacy.

American journal of respiratory and critical care medicine·2026
Same author

Immune checkpoint inhibitor pneumonitis presenting with multifocal nodular opacities.

Thorax·2026
Same author

Precision medicine in the era of CFTR modulator therapy: what comes next?

The European respiratory journal·2026
Same author

Treatment with elexacaftor/tezacaftor/ivacaftor does not alter SpiroNose-derived electronic breath profiles in children with cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Same author

Sputum Biomarkers of Inflammation to Track Acute Respiratory Events in School-Age Children with Cystic Fibrosis.

International journal of molecular sciences·2026
Same author

Impact of Effect Modification of Type 2 Inflammation and Sex on Asthma Exacerbation Rates.

CHEST pulmonary·2025

Related Experiment Video

Updated: Nov 9, 2025

Angiogenesis in the Ischemic Rat Lung
07:36

Angiogenesis in the Ischemic Rat Lung

Published on: February 8, 2013

15.8K

Arginine Therapy for Lung Diseases.

Jeremy A Scott1, Harm Maarsingh2, Fernando Holguin3

  • 1Occupational and Environmental Health, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.

Frontiers in Pharmacology
|April 9, 2021
PubMed
Summary

Nitric oxide (NO) plays key roles in lung health. Dysregulation of L-arginine and NO homeostasis contributes to pulmonary diseases, with therapies targeting L-arginine levels under investigation.

Keywords:
Pulmonary hypertensionairway hyperresponsivenessasthmaasymmetric dimethyl argininechronic obstructive pulmonary deseasecystic fibrosisremodeling

More Related Videos

A Rat Lung Transplantation Model of Warm Ischemia/Reperfusion Injury: Optimizations to Improve Outcomes
07:37

A Rat Lung Transplantation Model of Warm Ischemia/Reperfusion Injury: Optimizations to Improve Outcomes

Published on: October 28, 2021

3.2K
Isolation of Lung Retinoid-Containing Cells by Cell Sorting
07:47

Isolation of Lung Retinoid-Containing Cells by Cell Sorting

Published on: April 11, 2025

497

Related Experiment Videos

Last Updated: Nov 9, 2025

Angiogenesis in the Ischemic Rat Lung
07:36

Angiogenesis in the Ischemic Rat Lung

Published on: February 8, 2013

15.8K
A Rat Lung Transplantation Model of Warm Ischemia/Reperfusion Injury: Optimizations to Improve Outcomes
07:37

A Rat Lung Transplantation Model of Warm Ischemia/Reperfusion Injury: Optimizations to Improve Outcomes

Published on: October 28, 2021

3.2K
Isolation of Lung Retinoid-Containing Cells by Cell Sorting
07:47

Isolation of Lung Retinoid-Containing Cells by Cell Sorting

Published on: April 11, 2025

497

Area of Science:

  • Pulmonary Medicine
  • Biochemistry
  • Physiology

Background:

  • Nitric oxide (NO) is synthesized by nitric oxide synthases (NOSs) using L-arginine.
  • NO is crucial for lung development, airway/vascular tone, inflammation, and host defense.
  • Impaired L-arginine/NO balance is implicated in lung diseases like asthma, COPD, CF, and pulmonary hypertension.

Purpose of the Study:

  • To review the role of L-arginine/NO homeostasis in lung function and disease.
  • To explore therapeutic strategies aimed at restoring L-arginine/NO balance in pulmonary conditions.

Main Methods:

  • Literature review of studies on nitric oxide synthases (NOSs) and L-arginine metabolism.
  • Analysis of pre-clinical and clinical research on therapeutic interventions.

Main Results:

  • Altered L-arginine/NO homeostasis, influenced by NOS inhibitors and arginase competition, is linked to lung pathologies.
  • Therapeutic approaches focus on increasing L-arginine availability.

Conclusions:

  • Restoring L-arginine/NO homeostasis is a promising therapeutic avenue for various lung diseases.
  • Supplementation with L-arginine or L-citrulline, and arginase inhibition are key strategies.